biostudies-literatureWang CThe Science & Technology Development Fund of Tianjin Education Commission for Higher EducationThe Science &amp; Technology Development Fund of Tianjin Education Commission for Higher Education867https://www.ebi.ac.uk/biostudies/studies/S-EPMC11264757biostudies-literatureUnknown24(1)<h4>Objective</h4>To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.<h4>Design</h4>Open-label, prospective, multi-center phase II trial.<h4>Setting</h4>Three institutions.<h4>Participants</h4>Fifty-four patients scheduled to receive CapeOX chemotherapy.<h4>Interventions</h4>Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.<h4>Main outcome measures</h4>The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete controlBMC cancerProlonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.PMC112647572021KJ204Sun LJiang ZLi YPan ZYan ZZhang JWang BWang CQuan MLan LZhuang YfalseProlonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.<h4>Objective</h4>To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.<h4>Design</h4>Open-label, prospective, multi-center phase II trial.<h4>Setting</h4>Three institutions.<h4>Participants</h4>Fifty-four patients scheduled to receive CapeOX chemotherapy.<h4>Interventions</h4>Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.<h4>Main outcome measures</h4>The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control2024-01-01T00:00:00Z2024 Jul2026-06-01T20:37:45.481Z2026-05-22T03:07:42.328ZS-EPMC112647573902616510.1186/s12885-024-12616-9